Fundraising FoxOphthaFund
Venture capitalCharleston · Pre-Seed–Series A
Find your way into OphthaFund
Sign up to find every way you can get introduced to OphthaFund
- Your email: who you already know at OphthaFund, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the OphthaFund team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
The firm leverages deep expertise in ophthalmology and biotechnology to invest in specialized companies within these sectors. The team provides value-add support through drug development knowledge and access to a network of investors, partners, and subject matter experts.
Source: firm website, verified Aug 7, 2026.
What they invest in
from 6 of 11 portfolio companiesBiotech ×6Medical Devices ×4Healthtech ×2Deep Tech ×1Digital Health ×1
HQs:United States×5Switzerland×1
Investments · 11 tracked
founders shown can be your intro pathForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months.
BiotechHealthtechMedical DevicesMobile, US
Alan Franklin(Ophthalmologist, Vitreoretinal Diseases and Surgery)inRAJ MATURI(Director)NEIL DONNENFELD(Director)RUBEN TIMMONS(Director)BARRY BUTLER(Director)AMIR SHOJAEI(Director)
PartnerTom Mather· solo GP
Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment.
BiotechDeep TechMedical DevicesSeattle, US
Garry Redlich(CEO & MD, Co-founder)inProf. Peter Andrews(Chairman, Co-founder)James Edward Rottsolk(Executive Officer, Director)Marion Koster(Chief Financial Officer and Company Secretary)inBrian William Ziegelaar(Executive Officer)
BoardDaniel David Syrdal(Director)
PartnerTom Mather· solo GP
Biotechnology company developing treatments for ophthalmic diseases, focusing on dry eye through a topical ophthalmology platform.
BiotechSan Francisco, US
Tom Gadek(Founder)inChristopher J. Murphy(Director)Charles O'Neill(Executive Officer, Director)Tanya Shnaydman(Executive Officer)
PartnerTom Mather· solo GP
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
PartnerTom Mather· solo GP
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLC+3 more
Premark Pharma develops therapeutic candidates for ophthalmologic conditions including blepharitis and dry eye disease.
BiotechDigital HealthMedical Devices
PartnerTom Mather· solo GP
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Advanced Liquid LogicAllysta PharmaceuticalsBlink CNSElucida OncologyEncore PharmaceuticalsMyze
Frequently asked questions
- How many investments has OphthaFund made?
- OphthaFund has 11 tracked investments.
- What stage does OphthaFund invest at?
- OphthaFund invests at the Pre-Seed, Seed, Series A stages.
- What sectors does OphthaFund focus on?
- OphthaFund focuses on Biotech, Healthtech, Medical Devices.
- Where is OphthaFund located?
- OphthaFund is headquartered in Charleston, US.
- Does OphthaFund lead rounds?
- Yes, OphthaFund leads investment rounds.
- Who does OphthaFund co-invest with?
- OphthaFund most often shares deals with ExSight Ventures, Invest Michigan, Michigan Capital Network, among 6 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.